HIV and AIDS Articles
| |
FDA-approved
Treatments Experimental
Treatments
Top
New Articles
Guidelines |  |
PRO 140 and PRO 2000 PRO 140 is a humanized monoclonal antibody designed to block the ability of HIV to infect cells by inhibiting virus-cell binding. Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study - 9/28/07 Tolerability and Antiviral Efficacy of CCR5 Monoclonal Antibody PRO 140 - 8/10/07 Progenics Announces Results from First Clinical Trial of CCR5 Inhibitor PRO 140 - 5/04/07 Experimental Entry Inhibitor PRO 140 Wins "Fast Track" Designation from FDA - 2/28/06 PRO 2000 Microbicide Appears to Reduce Vaginal Inflammation - 2/23/07
|
| ||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||
